drugset

drugset / Trial / NCT06288893

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

NCT06288893 ↗

Phase 2 Unknown 30 enrolled JKT Biopharma Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets

Timeline

Start: 2024-04-01
Primary completion: 2024-08-01
Completion: 2025-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	SHEN211 Tablets	Unknown	110 mg	Oral

Indications